280 related articles for article (PubMed ID: 32178720)
1. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.
Lopens S; Krawczyk M; Papp M; Milkiewicz P; Schierack P; Liu Y; Wunsch E; Conrad K; Roggenbuck D
Auto Immun Highlights; 2020 Mar; 11(1):6. PubMed ID: 32178720
[TBL] [Abstract][Full Text] [Related]
2. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Wunsch E; Norman GL; Milkiewicz M; Krawczyk M; Bentow C; Shums Z; Mahler M; Lopens S; Reinhold D; Franke A; Schramm C; Roggenbuck D; Milkiewicz P
Aliment Pharmacol Ther; 2021 Jan; 53(2):302-313. PubMed ID: 33159471
[TBL] [Abstract][Full Text] [Related]
3. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
4. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.
Sowa M; Kolenda R; Baumgart DC; Pratschke J; Papp M; Tornai T; Suchanski J; Bogdanos DP; Mytilinaiou MG; Hammermann J; Laass MW; Conrad K; Schramm C; Franke A; Roggenbuck D; Schierack P
Front Immunol; 2018; 9():1959. PubMed ID: 30233574
[No Abstract] [Full Text] [Related]
5. Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.
Roggenbuck D; Reinhold D; Baumgart DC; Schierack P; Conrad K; Laass MW
Adv Clin Chem; 2016; 77():77-101. PubMed ID: 27717419
[TBL] [Abstract][Full Text] [Related]
6. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).
Stinton LM; Bentow C; Mahler M; Norman GL; Eksteen B; Mason AL; Kaplan GG; Lindkvist B; Hirschfield GM; Milkiewicz P; Cheung A; Janssen HL; Fritzler MJ
PLoS One; 2014; 9(11):e112877. PubMed ID: 25397578
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood.
Maggiore G; Riva S; Sciveres M
Minerva Gastroenterol Dietol; 2009 Mar; 55(1):53-70. PubMed ID: 19212308
[TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis: a clinical update.
Williamson KD; Chapman RW
Br Med Bull; 2015 Jun; 114(1):53-64. PubMed ID: 25981516
[TBL] [Abstract][Full Text] [Related]
9. Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis.
Crescente JG; Dellavance A; Diniz MA; Carrilho FJ; Andrade LEC; Cançado ELR
Clinics (Sao Paulo); 2021; 76():e2228. PubMed ID: 33567045
[TBL] [Abstract][Full Text] [Related]
10. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.
Bjarnason I; Hayee B; Pavlidis P; Kvasnovsky C; Scalori A; Sisson G; Charlesworth A; Shaikh H; Bjornsson E; Heneghan MA
EBioMedicine; 2015 Oct; 2(10):1523-7. PubMed ID: 26629548
[TBL] [Abstract][Full Text] [Related]
11. [Autoimmune hepatitis and overlap syndrome: diagnosis].
Berg PA; Klein R
Praxis (Bern 1994); 2002 Aug; 91(34):1339-46. PubMed ID: 12233264
[TBL] [Abstract][Full Text] [Related]
12. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
Bayraktar Y; Arslan S; Saglam F; Uzunalimoglu B; Kayhan B
Hepatogastroenterology; 1998; 45(24):2064-72. PubMed ID: 9951867
[TBL] [Abstract][Full Text] [Related]
13. Serological biomarkers for management of primary sclerosing cholangitis.
Tornai D; Ven PL; Lakatos PL; Papp M
World J Gastroenterol; 2022 Jun; 28(21):2291-2301. PubMed ID: 35800183
[TBL] [Abstract][Full Text] [Related]
14. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Tornai T; Tornai D; Sipeki N; Tornai I; Alsulaimani R; Fechner K; Roggenbuck D; Norman GL; Veres G; Par G; Par A; Szalay F; Lakatos PL; Antal-Szalmas P; Papp M
Sci Rep; 2018 Jan; 8(1):399. PubMed ID: 29321484
[TBL] [Abstract][Full Text] [Related]
15. [Autoimmune liver diseases and their overlap syndromes].
Strassburg CP
Praxis (Bern 1994); 2006 Sep; 95(36):1363-81. PubMed ID: 16989180
[TBL] [Abstract][Full Text] [Related]
16. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases.
Muratori P; Muratori L; Guidi M; Maccariello S; Pappas G; Ferrari R; Gionchetti P; Campieri M; Bianchi FB
Clin Exp Immunol; 2003 Jun; 132(3):473-6. PubMed ID: 12780695
[TBL] [Abstract][Full Text] [Related]
17. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.
de Vries AB; Janse M; Blokzijl H; Weersma RK
World J Gastroenterol; 2015 Feb; 21(6):1956-71. PubMed ID: 25684965
[TBL] [Abstract][Full Text] [Related]
18. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.
Mazza S; Soro S; Verga MC; Elvo B; Ferretti F; Cereatti F; Drago A; Grassia R
World J Hepatol; 2021 Dec; 13(12):1828-1849. PubMed ID: 35069993
[TBL] [Abstract][Full Text] [Related]
19. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies to glutathione S-transferase theta 1 in patients with primary sclerosing cholangitis and other autoimmune diseases.
Ardesjö B; Hansson CM; Bruder CE; Rorsman F; Betterle C; Dumanski JP; Kämpe O; Ekwall O
J Autoimmun; 2008 Jun; 30(4):273-82. PubMed ID: 18242955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
